Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
KRW 142300.0
(1.14%)
KRW 142300.0
(1.14%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 13.19 Billion KRW | -75.78% |
| 2022 | 54.48 Billion KRW | 2144.32% |
| 2021 | 2.42 Billion KRW | 107.62% |
| 2020 | -31.86 Billion KRW | 12.52% |
| 2019 | -36.42 Billion KRW | -16.3% |
| 2018 | -31.31 Billion KRW | 44.64% |
| 2017 | -56.57 Billion KRW | -35.85% |
| 2016 | -41.64 Billion KRW | -37.75% |
| 2015 | -30.23 Billion KRW | -8.14% |
| 2014 | -27.95 Billion KRW | -66.95% |
| 2013 | -16.74 Billion KRW | -168.51% |
| 2012 | -6.23 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -48.02 Billion KRW | -1172.54% |
| 2024 Q1 | 4.47 Billion KRW | -66.07% |
| 2023 Q2 | 57.29 Billion KRW | 1.29% |
| 2023 Q1 | 56.56 Billion KRW | 3.81% |
| 2023 FY | 13.19 Billion KRW | -75.78% |
| 2023 Q4 | 13.19 Billion KRW | -72.48% |
| 2023 Q3 | 47.94 Billion KRW | -16.31% |
| 2022 Q4 | 54.48 Billion KRW | 29.9% |
| 2022 FY | 54.48 Billion KRW | 2144.32% |
| 2022 Q3 | 41.94 Billion KRW | 33.29% |
| 2022 Q2 | 31.47 Billion KRW | -6.21% |
| 2022 Q1 | 33.55 Billion KRW | 1282.12% |
| 2021 Q3 | -11.48 Billion KRW | 56.43% |
| 2021 Q4 | 2.42 Billion KRW | 121.14% |
| 2021 FY | 2.42 Billion KRW | 107.62% |
| 2021 Q2 | -26.36 Billion KRW | -172.76% |
| 2021 Q1 | -9.66 Billion KRW | 70.51% |
| 2020 Q1 | -31.47 Billion KRW | 15.12% |
| 2020 Q3 | -28.19 Billion KRW | -23.27% |
| 2020 Q4 | -32.77 Billion KRW | -16.25% |
| 2020 Q2 | -22.87 Billion KRW | 27.33% |
| 2020 FY | -31.86 Billion KRW | 12.52% |
| 2019 Q3 | -38.45 Billion KRW | -55.65% |
| 2019 Q2 | -24.7 Billion KRW | 4.98% |
| 2019 Q1 | -26 Billion KRW | 16.97% |
| 2019 FY | -36.42 Billion KRW | -16.3% |
| 2019 Q4 | -37.08 Billion KRW | 3.58% |
| 2018 Q2 | -49.74 Billion KRW | 3.07% |
| 2018 Q1 | -51.32 Billion KRW | 9.28% |
| 2018 Q4 | -31.31 Billion KRW | 14.25% |
| 2018 FY | -31.31 Billion KRW | 44.64% |
| 2018 Q3 | -36.52 Billion KRW | 26.59% |
| 2017 FY | -56.57 Billion KRW | -35.85% |
| 2017 Q2 | -47.93 Billion KRW | -2.57% |
| 2017 Q3 | -50 Billion KRW | -4.32% |
| 2017 Q4 | -56.57 Billion KRW | -13.12% |
| 2017 Q1 | -46.73 Billion KRW | -12.22% |
| 2016 Q3 | -39.63 Billion KRW | -12.25% |
| 2016 FY | -41.64 Billion KRW | -37.75% |
| 2016 Q1 | -32.58 Billion KRW | -7.77% |
| 2016 Q4 | -41.64 Billion KRW | -5.06% |
| 2016 Q2 | -35.31 Billion KRW | -8.38% |
| 2015 Q1 | -25.59 Billion KRW | 8.45% |
| 2015 Q4 | -30.23 Billion KRW | 0.85% |
| 2015 Q3 | -30.48 Billion KRW | -15.29% |
| 2015 Q2 | -26.44 Billion KRW | -3.33% |
| 2015 FY | -30.23 Billion KRW | -8.14% |
| 2014 Q1 | -17.38 Billion KRW | -3.85% |
| 2014 FY | -27.95 Billion KRW | -66.95% |
| 2014 Q3 | -26.89 Billion KRW | -8.38% |
| 2014 Q2 | -24.81 Billion KRW | -42.71% |
| 2014 Q4 | -27.95 Billion KRW | -3.93% |
| 2013 Q1 | 13.44 Billion KRW | 315.59% |
| 2013 Q2 | 15.2 Billion KRW | 13.1% |
| 2013 FY | -16.74 Billion KRW | -168.51% |
| 2013 Q3 | 10.11 Billion KRW | -33.47% |
| 2013 Q4 | -16.74 Billion KRW | -265.52% |
| 2012 FY | -6.23 Billion KRW | 0.0% |
| 2012 Q4 | -6.23 Billion KRW | 61.86% |
| 2012 Q3 | -16.34 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Hyundai Bioscience Co., Ltd. | 3.73 Billion KRW | -253.385% |
| ST Pharm Co.,Ltd. | 141.98 Billion KRW | 90.705% |
| ABL Bio Inc. | 15.87 Billion KRW | 16.859% |
| Cellid, Co., Ltd. | -1.38 Billion KRW | 1052.251% |